FDA grants priority review for BioMarin’s PALYNZIQ to treat adolescents with phenylketonuria (PKU)

The U.S. Food and Drug Administration has accepted BioMarin Pharmaceutical Inc.’s supplemental Biologics License Application for PALYNZIQ (pegvaliase-pqpz), granting Priority Review for expanding its use to adolescents aged 12–17 years living with phenylketonuria (PKU). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of February 28, 2026, signaling a faster path toward potentially making this enzyme therapy available to younger patients who face limited treatment options.

According to BioMarin, the submission includes results from the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine (Phe) levels compared to standard management. The company stated that adolescent participants treated with PALYNZIQ achieved both meaningful biochemical control and greater dietary flexibility—two outcomes that remain challenging for families managing PKU.

PALYNZIQ is currently approved in the United States for adults with uncontrolled blood Phe concentrations greater than 600 µmol/L despite dietary restriction. If approved for adolescents, the label expansion would mark the first new treatment option for teenage PKU patients in over a decade.

How BioMarin aims to address the treatment gap in adolescent PKU management

Phenylketonuria is a rare metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, which prevents the body from metabolizing the amino acid phenylalanine. Without tight dietary control, Phe accumulates to toxic levels, leading to neurological impairment, intellectual disability, and emotional disturbances.

The standard of care remains a severely Phe-restricted diet, often supplemented with amino acid-based medical foods. However, maintaining compliance with this regimen becomes increasingly difficult during adolescence, a stage marked by social and behavioral independence. BioMarin noted that adherence challenges frequently result in elevated Phe levels, affecting cognitive and emotional health.

By leveraging pegvaliase, a PEGylated recombinant enzyme that converts phenylalanine to harmless metabolites, PALYNZIQ targets the root biochemical imbalance in PKU rather than merely controlling dietary intake. Clinical results from the PEGASUS trial indicate that adolescents on PALYNZIQ achieved Phe reductions comparable to adults while maintaining or even increasing protein intake from natural foods.

Dr. Hank Fuchs, BioMarin’s President of Worldwide Research and Development, emphasized in company statements that adolescents “require effective, manageable treatments that can deliver meaningful and sustained reductions in blood Phe levels while improving quality of life.” The company has described this label expansion as both a scientific and social imperative, aiming to reduce the cognitive strain that PKU imposes on teenage patients and their caregivers.

Why the FDA’s priority review designation could reshape BioMarin’s regulatory and commercial strategy

The FDA’s Priority Review designation shortens the standard review period from ten months to six months, granted only to therapies that may offer significant improvements in safety or efficacy over existing treatments. In BioMarin’s case, the decision reflects the agency’s acknowledgment of the unmet clinical need among adolescents with PKU.

This development positions PALYNZIQ as BioMarin’s next major regulatory milestone following its earlier approvals for enzyme replacement therapies such as Vimizim and Brineura. The move aligns with the company’s broader rare-disease strategy to deepen market penetration through lifecycle management—expanding indications, age groups, and geographies to maximize therapeutic reach and commercial sustainability.

Market analysts see the review as a near-term catalyst for BioMarin’s stock (NASDAQ: BMRN), which has traded in a narrow range around $53 per share in recent sessions. As of October 29, the stock saw intraday movement between $52.94 and $54.71, closing slightly lower by 0.01%, suggesting that investors have yet to fully price in the potential upside from the adolescent indication.

Institutional sentiment around BioMarin remains moderately positive, buoyed by a robust rare-disease portfolio and steady revenue growth from its marketed products. Should PALYNZIQ secure approval for adolescents, the therapy’s eligible population would expand significantly, strengthening recurring revenue from a chronic-use product.

What experts say about BioMarin’s prospects and market positioning after the PALYNZIQ expansion

Industry experts have described the FDA’s acceptance as a logical progression for a therapy that already has a well-established adult safety profile and a strong clinical rationale for earlier intervention. Analysts at several healthcare research firms indicated that the adolescent market, though smaller in absolute size, represents a critical demographic for improving lifetime disease management and retention within BioMarin’s treatment ecosystem.

Some healthcare economists note that while PALYNZIQ’s Risk Evaluation and Mitigation Strategy (REMS) requirement—implemented to manage risks such as anaphylaxis—adds administrative complexity, the program has functioned effectively in adult populations. This precedent, they suggest, should help regulators and clinicians adapt the same framework for adolescent patients with adequate monitoring and caregiver training.

The therapy’s subcutaneous administration model and patient-tailored dosing flexibility are likely to appeal to specialized metabolic centers already experienced with PKU management. Physicians surveyed in prior market analyses cited the burden of dietary restriction as one of the main drivers for adopting enzymatic therapy, especially in cases where cognitive or psychosocial impacts compromise dietary adherence.

BioMarin’s move to expand PALYNZIQ also coincides with the company’s European regulatory efforts. The firm is preparing a similar submission to the European Medicines Agency (EMA) to extend adolescent use in the European Union, aligning with its global commercialization strategy for rare metabolic diseases.

How investor sentiment and rare-disease market dynamics could influence BioMarin’s valuation in 2026

The PALYNZIQ expansion could play an outsized role in shaping BioMarin’s valuation trajectory heading into 2026. Analysts project that if approved, the adolescent indication could add $100 million to $150 million in incremental annual revenue potential by 2027, depending on uptake and payer coverage.

The timing of the PDUFA date—February 2026—positions this milestone within the same horizon as several other BioMarin catalysts, including additional Phase 3 data readouts for its gene therapy programs. This clustering of regulatory events could create a series of re-rating opportunities for investors looking at BioMarin’s medium-term growth narrative.

From a sentiment perspective, BioMarin’s expansion into younger cohorts is viewed as a move to strengthen brand durability and patient retention. Because PKU is a lifelong disorder, introducing treatment earlier may secure longer-term adherence and brand loyalty. Investors view this as an efficient way to expand lifetime value per patient while addressing a clinically underserved group.

However, analysts remain cautious about pricing and reimbursement outcomes. Given PALYNZIQ’s biologic nature and the healthcare system’s increasing focus on cost containment in rare diseases, pricing negotiations with payers will be pivotal in determining the therapy’s adoption curve post-approval.

Still, BioMarin’s consistent track record of securing reimbursement for high-value orphan therapies suggests it is well-positioned to navigate these complexities. Market watchers expect that early dialogue with insurers—combined with patient-assistance initiatives—could facilitate access once approval is granted.

What this milestone means for the broader PKU community and BioMarin’s rare-disease leadership

For patients, the FDA’s decision represents more than a regulatory milestone—it symbolizes progress toward a future where PKU management is less about dietary compromise and more about biochemical control. If PALYNZIQ gains approval for adolescents, clinicians could tailor treatment plans that allow greater dietary freedom and reduce the social stigma associated with lifelong food restrictions.

Patient-advocacy organizations, including the National PKU Alliance, have long pushed for expanded access to enzyme-based therapies in younger populations. They argue that early biochemical normalization has long-term benefits for cognitive development and emotional wellbeing. The FDA’s willingness to prioritize review of this sBLA indicates growing recognition of these patient-centric outcomes as integral to regulatory decision-making.

From a strategic standpoint, BioMarin’s leadership in PKU parallels its broader reputation in the rare-disease field, where it continues to leverage deep expertise in enzyme and gene-based therapies. The company’s success with PALYNZIQ in adolescents could reinforce its standing as a benchmark innovator among mid-cap biopharmaceuticals specializing in inherited metabolic disorders.

The next critical milestone will be the FDA’s PDUFA decision in February 2026, which could determine whether BioMarin can begin marketing PALYNZIQ to U.S. adolescents later that year. Beyond approval, the company’s ability to scale educational programs for clinicians, patients, and caregivers will likely define its success in realizing PALYNZIQ’s full market potential.

In the meantime, both investors and the PKU community will be watching closely as BioMarin navigates the final phase of regulatory review. If the FDA grants approval, it would not only expand the therapeutic toolkit for PKU but also reaffirm the company’s broader leadership in bringing transformative rare-disease solutions to underserved patient populations.